Epigenetic modification in the expression of p73 p73 - epigenetic target for anticancer therapy

  • Faiza Naseer | faiza.naseer@ymail.com Shifa College of Pharmaceutical Sciences, Shifa Tameer e Millat University, Islamabad, Pakistan.
  • Mohammad Saleem Faculty of Pharmaceutical Sciences, Punjab University, Lahore, Pakistan.


A p73 is a new member of p53 family of transcription factor, having two types. First is TAp73, transcriptionally active and expressed via upstream promoter as a tumor suppressor and vital apoptotic inductor, it also has a key role in cell cycle arrest/differentiation and Second is ΔNp73 that is transcriptionally inactive and expressed via downstream regulator as oncogenes. Both types are expressed in various isoforms, which originate from alternative splicing events at the C-terminus. Upon DNA damage, posttranslational modifications cause conformational changes in various amino acid residues via induction or inhibition of various proteins, which are present in the structural domains of p73. These modifications may cause up- or down-regulation of p73 expression levels, as well as alters the transcriptional activity and/or stability of the protein. In this review, we have made an effort to assemble all existing data regarding the role of p73, its modification and after effects in cancer.



PlumX Metrics


Download data is not yet available.
p73, post translational modification, methylation, phosphorylation, acetylation, ubiqutination.
  • Abstract views: 909

  • PDF: 544
  • HTML: 14
How to Cite
Naseer, F., & Saleem, M. (2019). Epigenetic modification in the expression of p73 p73 - epigenetic target for anticancer therapy. Oncology Reviews, 13(2). https://doi.org/10.4081/oncol.2019.421